Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mavorixafor for treating WHIM syndrome [ID3946]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Bentracimab for reversing the antiplatelet activity of ticagrelor [ID6344]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inebilizumab for treating immunoglobulin G4-related disease [TSID12107]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avexitide for treating hypoglycaemia after bariatric surgery [ID6725]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Etavopivat for treating sickle cell disease in people 12 years and over [ID6698]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Luspatercept for treating anaemia caused by myelodysplastic syndromes (including review of TA844) [ID6696]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Luspatercept for treating anaemia caused by myelofibrosis [ID6697]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rusfertide for treating polycythaemia vera in people having phlebotomy [ID6709]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Luspatercept for treating haemoglobin H disease [ID6714]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Crovalimab for treating atypical haemolytic uraemic syndrome [TSID12386]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC